Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Puma Biotechnology (PBYI) Receivables - Net (2017 - 2025)

Puma Biotechnology's Receivables - Net history spans 9 years, with the latest figure at $53.7 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 67.61% year-over-year to $53.7 million; the TTM value through Dec 2025 reached $53.7 million, up 67.61%, while the annual FY2025 figure was $53.7 million, 67.61% up from the prior year.
  • Receivables - Net reached $53.7 million in Q4 2025 per PBYI's latest filing, up from $33.6 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $54.6 million in Q3 2024 to a low of $23.8 million in Q3 2021.
  • Average Receivables - Net over 5 years is $33.0 million, with a median of $30.9 million recorded in 2021.
  • Peak YoY movement for Receivables - Net: surged 88.59% in 2024, then crashed 38.57% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $32.5 million in 2021, then increased by 24.05% to $40.4 million in 2022, then rose by 18.56% to $47.8 million in 2023, then plummeted by 33.08% to $32.0 million in 2024, then skyrocketed by 67.61% to $53.7 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Receivables - Net are $53.7 million (Q4 2025), $33.6 million (Q3 2025), and $25.9 million (Q2 2025).